WO2012144755A3 - 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법 - Google Patents

리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법 Download PDF

Info

Publication number
WO2012144755A3
WO2012144755A3 PCT/KR2012/002454 KR2012002454W WO2012144755A3 WO 2012144755 A3 WO2012144755 A3 WO 2012144755A3 KR 2012002454 W KR2012002454 W KR 2012002454W WO 2012144755 A3 WO2012144755 A3 WO 2012144755A3
Authority
WO
WIPO (PCT)
Prior art keywords
cognitive impairment
mild cognitive
diagnosis
lipocalin
expression level
Prior art date
Application number
PCT/KR2012/002454
Other languages
English (en)
French (fr)
Other versions
WO2012144755A2 (ko
Inventor
석경호
이호원
최지혜
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Priority to US14/112,836 priority Critical patent/US20140057267A1/en
Publication of WO2012144755A2 publication Critical patent/WO2012144755A2/ko
Publication of WO2012144755A3 publication Critical patent/WO2012144755A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 리포칼린 2 유전자의 mRNA 또는 단백질 발현 수준을 측정하는 제제를 포함하는 경도 인지 장애 진단용 조성물 및 경도 인지 장애 진단용 키트와 이를 이용하여 경도 인지장애 진단을 위한 정보를 제공하는 방법에 관한 것이다. 본 발명에 따른 리포칼린 2 유전자의 mRNA 또는 단백질 발현 수준을 측정하는 제제는 정상인 및 알츠하이머 질환 환자군과 비교하여 경도 인지 장애 환자군에서 높은 발현 수준을 나타내는 리포칼린 2 의 발현 수준을 측정함으로써, 경도 인지 장애 환자를 특이적으로 식별할 수 있으며, 특히 알츠하이머 질환 환자군과 경도 인지 장애 환자군을 식별할 수 있는 효과가 있다.
PCT/KR2012/002454 2011-04-22 2012-04-02 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법 WO2012144755A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/112,836 US20140057267A1 (en) 2011-04-22 2012-04-02 Composition and kit for the diagnosis of mild cognitive impairment, which measure an expression level of lipocalin-2, and method for providing information for the diagnosis of mild cognitive impairment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110037775A KR101295019B1 (ko) 2011-04-22 2011-04-22 리포칼린 2 수준을 측정하는 것을 포함하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법.
KR10-2011-0037775 2011-04-22

Publications (2)

Publication Number Publication Date
WO2012144755A2 WO2012144755A2 (ko) 2012-10-26
WO2012144755A3 true WO2012144755A3 (ko) 2013-01-10

Family

ID=47042017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002454 WO2012144755A2 (ko) 2011-04-22 2012-04-02 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법

Country Status (3)

Country Link
US (1) US20140057267A1 (ko)
KR (1) KR101295019B1 (ko)
WO (1) WO2012144755A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101962180B1 (ko) * 2018-11-16 2019-03-26 경상대학교산학협력단 TonEBP 항체를 유효성분으로 함유하는 경도인지장애 진단용 조성물
KR20230105418A (ko) 2022-01-04 2023-07-11 동의대학교 산학협력단 개망초 추출물을 이용한 후각상피세포자극을 통한 후각기능 개선 및 이를 포함하는 집중력, 인지력, 기억력 개선용 조성물과 이를 포함하는 기능성 식품

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080076717A (ko) * 2008-01-16 2008-08-20 경북대학교 산학협력단 퇴행성 신경질환의 진단을 위한 리포칼린 2의 신규한 용도
KR20090029338A (ko) * 2007-09-18 2009-03-23 한국생명공학연구원 간암 마커로서의 ｌｃｎ2 유전자, 단백질 및 간암 진단키트
KR20100023117A (ko) * 2008-08-21 2010-03-04 경북대학교 산학협력단 뇌 손상 치료를 위한 리포칼린 2의 신규한 용도
US20100159486A1 (en) * 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900936B1 (fr) * 2006-05-15 2013-01-04 Exonhit Therapeutics Sa Procede et methodes de detection de la maladie d'alzheimer
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009108762A2 (en) * 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100159486A1 (en) * 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
KR20090029338A (ko) * 2007-09-18 2009-03-23 한국생명공학연구원 간암 마커로서의 ｌｃｎ2 유전자, 단백질 및 간암 진단키트
KR20080076717A (ko) * 2008-01-16 2008-08-20 경북대학교 산학협력단 퇴행성 신경질환의 진단을 위한 리포칼린 2의 신규한 용도
KR20100023117A (ko) * 2008-08-21 2010-03-04 경북대학교 산학협력단 뇌 손상 치료를 위한 리포칼린 2의 신규한 용도

Also Published As

Publication number Publication date
US20140057267A1 (en) 2014-02-27
KR101295019B1 (ko) 2013-08-09
KR20120119669A (ko) 2012-10-31
WO2012144755A2 (ko) 2012-10-26

Similar Documents

Publication Publication Date Title
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2010115843A3 (en) Pharmaceutical composition
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2012078591A8 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2987807A3 (en) Antibodies recognising phospho-tau
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
WO2012061655A3 (en) System and process for optimization of dentures
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2010097186A8 (en) Use of s-erbb-3 as a marker for cancer
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
MX2013003929A (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer.
WO2013011294A3 (en) Diagnosis of alzheimer's disease
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
WO2013009146A3 (ko) 당뇨망막병증 진단용 마커 및 이의 용도
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2010129665A3 (en) Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
WO2013009143A3 (ko) 당뇨망막병증 진단용 마커 및 이의 용도
WO2012144755A3 (ko) 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12774057

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14112836

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12774057

Country of ref document: EP

Kind code of ref document: A2